Compare Noble Corporation plc (NE) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Noble Corporation plc vs Recursion Pharmaceuticals Inc — how do they compare? Noble Corporation plc trades at $45.83 (market cap $7.33B), while Recursion Pharmaceuticals Inc trades at $3.24 (market cap $1.86B). The key difference: Noble Corporation plc is far larger — about 3.9× Recursion Pharmaceuticals Inc's market cap, and Noble Corporation plc pays a 4.36% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| NE | RXRX | |
|---|---|---|
Market Cap | $7.33B | $1.86B |
Sector | Technology | Health |
52-Week High | $54.37 | $6.79 |
52-Week Low | $26.70 | $2.84 |
Enterprise Value | $8.76B | $1.38B |
Dividend Yield | 4.36% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Noble Corporation (NE) trades at $45.89, up 0.61% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $46.00. Recent earnings show mixed quarterly results, with a Q1 2026 beat but Q2 and Q4 2025 misses, while annual revenue declined to $3.1 billion in 2026 from $3.3 billion in 2025, and net income fell to $150 million. The company maintains positive cash flow from operations and announced a $0.50 dividend payable in September 2026.
Outlook is cautious due to earnings volatility and revenue contraction, offset by strong cash generation and analyst support. Key risks include ongoing legal investigations and competitive pressures in the offshore drilling sector. The stock presents a balanced opportunity with moderate upside to the price target, but investors should monitor earnings consistency and legal developments.
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, maintaining a negative profit margin of -961.97%. Recent news highlights AI-driven drug discovery progress with Genentech partnership milestones and pipeline expansion in oncology and rare diseases.
Outlook remains speculative with high revenue growth potential from AI platform partnerships offset by persistent losses and cash burn. Investment opportunity hinges on clinical pipeline success, while risks include slow revenue traction and competitive pressures in AI-biotech. Analyst consensus is mixed with 40% buy ratings amid cautious optimism on long-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
